CytomX Therapeutics is a pioneer in conditionally activated, masked PROBODY therapeutics designed to localize drug activity to the tumor microenvironment, thereby widening the therapeutic window for highly potent payloads. The company's lead asset, Varseta-M (CX-2051), has demonstrated highly promising clinical efficacy in late-line colorectal cancer (CRC) with confirmed objective response rates up to 32% and median progression-free survival of ~7.1 months. Following a massive $234 million net equity raise in March 2026, CytomX has eliminated near-term funding risks, extending its cash runway into at least the second half of 2028. While the wind-down of legacy collaboration obligations has caused a temporary drop in quarterly revenues, the company's robust platform, deep pipeline, and active partnerships with Regeneron, Amgen, and Moderna position it as a highly attractive, well-capitalized biotech with multiple near-term clinical catalysts.